By in

Sativa hires retail expert Chris Jones to launch Sativa’s Goodbody & Blunt wellness centres

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa hires retail expert Chris Jones to launch Sativa’s Goodbody & Blunt wellness centres

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has appointed, with immediate effect, retail management professional Chris Jones to launch its wellness centres, branded Goodbody & Blunt, which will offer customers a variety of CBD wellness products in drop-in cafes that will offer in-house or retail purchases.  Chris will be Managing Director of Sativa Wellness Centres Limited and the expansion plan will be funded from the Company’s existing resources, including the proceeds of the Share Placing completed in October 2018. 

Chris’ experiencecentres on the vaping and mobile phone industries, where he developed strong relationships in key markets, including Germany and the USA, and helped build and expand retail businesses in competitive market conditions.

Recently, Chris worked as a consultant sales director for one of the largest vaping companies in the UK, which has over 110 stores, and also consulted for Northern Ireland vaping company Ziggicigwith over 20 stores.  

His mobile phone experience includes being a Sales Director at Nokia Mobile Phones UK, where he helped Nokia to achieve market leader status, and also helped to build the mobile phone businesses of Dextra Mobile Accessories and Phones 4U.  In addition to this, Chris helped build Swindon-based mobile service provider Cellular Operations to a subscriber base of 500,000, before it was acquired by Vodafone. 

Geremy Thomas, founder and Chief Executive Officer of Sativa, said: “Chris’ experience of growing businesses in these highly competitive markets, coupled with very strong retail and franchise operational knowledge, is an ideal fit for Sativa’s aggressive market development plans for its Goodbody & Blunt wellness centres.  The model will be proofed with two to three retail outlets, then the Company has the option to roll it out further or as a franchise. 

 “These stores will offer customers CBD wellness products including oils that you can add to beverages such as your coffee, balms, vapes and several other new in demand products.  These stores will also constitute a key component for the Company’s seed-to-consumer strategy.”

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends –

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

NEX Exchange Corporate Adviser

Guy Miller and Lucy Williams

Peterhouse Capital Limited 

+44 (0) 20 7469 0930

gm@peterhousecap.com

Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark /

Alejandra Campuzano

Abchurch Switchboard

SativaInvestments@abchurch-group.com 

 

+44 (0) 20 7469 4633 / 4634

 

 

+44 (0) 20 7469 4630

www.abchurch-group.com

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has already made six investments to date, these being Canadian-based and dual-listed emerging pharmaceutical company,Veritas Pharma Inc. (“Veritas Pharma” or “Veritas”), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. (“RDT”), which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture withGermany’s Lexamed GmbH, and an option on a 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use. 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativagroup.co.uk